17 -2 (34/1) 2021 — Baratova M.S., Ataeva M.A., — DIAGNOSTIC CRITERIA FOR CORONAVIRUS INFECTION IN CARDIOVASCULAR DISEASES AND PROTECTING PERSONNEL FROM INFECTION

DIAGNOSTIC CRITERIA FOR CORONAVIRUS INFECTION IN CARDIOVASCULAR DISEASES AND PROTECTING PERSONNEL FROM INFECTION

Baratova M.S., Bukhara State Medical Institute

Ataeva M.A., Bukhara State Medical Institute

Musaeva D.M. Bukhara State Medical Institute

Resume

Given the risk of cardiovascular complications in COVID-19, including exacerbation of pre-existing heart disease, acute myocardial injury, and drug-related cardiac arrhythmias, echocardiography (EchoCG) is one of the main diagnostic methods for evaluating patients with suspected infection or confirmed disease.

Conducting bedside echocardiography, which may be of diagnostic value if myocarditis is suspected as one of the manifestations of heart damage in coronavirus infection.

Key words: coronavirus infection, cardiovascular system, echocardiography, ultrasound examination, myocarditis.

First page

92

Last page

98

For citation: Baratova M.S., Ataeva M.A., Musaeva D.M. Diagnostic criteria for coronavirus infection in cardiovascular diseases and protecting personnel from infection//New Day in Medicine 2(34/1)2021 92-98 https://cutt.ly/fbRGHsi

LIST OF REFERENCES

1. “Product Information. Fortovase (saquinavir)” Roche Laboratories, Nutley, NJ.
2. “Product Information. Lexiva (fosamprenavir).” GlaxoSmithKline, Research Triangle Park, NC.
3. “Product Information. Norvir (ritonavir).” Abbott Pharmaceutical, Abbott Park, IL.
4. “Product Information. Prezista (darunavir).” Ortho Biotech Inc, Bridgewater, NJ.
5. “Product Information. Viracept (nelfinavir).” Agouron Pharma Inc, La Jolla, CA.
6. “Product Information. Xarelto (rivaroxaban).” Bayer Inc, Toronto I.A.
7. Bautin A.E., Mazurok V.A., Osovskikh V.V., Afanasyeva K.Yu. Hemodynamic effects of the alveolar mobilization maneuver in cardiac surgery patients with left ventricular systolic dysfunction // Anesthesiology and Reanimatology. – 2014. – T. 59. No. 6. – S. 43-48.
8. Temporary guidelines of the Ministry of Health of Russia “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”, version 4 of 03/27/2020.
9. Mareev V.Yu.. Lecture on the topic: “COVID-19 and cardiovascular diseases: issues of diagnosis and treatment.” 04/14/2020 https://www.youtube.com/watch?v=Fe8MN_P_yCQ&feature=share&fbclid=IwAR1ob5ff33d60hMLm_f3WObt2tsf7QuUK5EqSfXd_7norN49s2KOX8sJXY
10. Shlyakhto E.V., Konradi A.O., Villevalde S.V., Zvartau N.E., Yakovlev A.N., et al. // Guidelines for the diagnosis and treatment of circulatory system diseases (CVD) in the context of the COVID pandemic -19 //2020,P.41.
11. A statement from the International Society of Hypertension on COVID-19. https://ishworld.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/12.
12. Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med 2016;36:78-80.
13. Alon D, Stein GY, Korenfeld R, Fuchs S. Predictors and outcomes of infection-related hospital admissions of heart failure patients. PLoS One 2013;8:e72476.
14. WHO Director-General’s opening remarks at the media briefing on COVID-19. [Published online 11 march 2020]. [Electronic resource]. URL: https://www.who.int/dg/speeches/detail/who-director-general-s-openingremarks-at-the-media-briefing-on-covid-19-11-march-2020. Accessed March 19, 2020.
15. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. doi:10.1016/S 0140-6736(20)30566-3
16. Clerkin K.J., Fried J.A., Raikhelkar J., Sayer G., Griffin J.M., Masoumi A. et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation.2020;141(20):1648-1655. doi.org/10.1161/CIRCULATIONAHA.120.046941
17. Verity R., Okell L.C., Dorigatti I., Winskill P., Whittaker C., Imai N. et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. /Lancet Infect Dis. 2020;20(6):669-677. doi.org/10.1016/S 1473-3099(20)30243-7
18. Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-260. doi.org/ 10.1038/s41569-020-0360-5
19. Xiong T.Y., Redwood S., Prendergast B., Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;14;41(19):1798-1800. doi.org/10.1093/eurheartj/ ehaa231
20. Yu C.M., Wong R.S., Wu E.B., Kong S.L., Wong J., Yip G.W. et al. Cardiovascular complications of severe acute respiratory syndrome. //Postgrad Med J. 2006;82(964):140-144. doi.org/10.1136/ pgmj.2005.037515